These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 9028635

  • 21. Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT.
    Ricci A, Veglio F, Amenta F.
    J Neuroimmunol; 1995 May; 58(2):139-44. PubMed ID: 7759603
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Expression of dopamine receptors in the subthalamic nucleus of the rat: characterization using reverse transcriptase-polymerase chain reaction and autoradiography.
    Flores G, Liang JJ, Sierra A, Martínez-Fong D, Quirion R, Aceves J, Srivastava LK.
    Neuroscience; 1999 May; 91(2):549-56. PubMed ID: 10366012
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dopamine D5 receptors in human peripheral blood lymphocytes: a radioligand binding study.
    Ricci A, Amenta F.
    J Neuroimmunol; 1994 Aug; 53(1):1-7. PubMed ID: 8051291
    [Abstract] [Full Text] [Related]

  • 26. Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
    Tice MA, Hashemi T, Taylor LA, Duffy RA, McQuade RD.
    Pharmacol Biochem Behav; 1994 Nov; 49(3):567-71. PubMed ID: 7862709
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.
    Wood M, Dubois V, Scheller D, Gillard M.
    Br J Pharmacol; 2015 Feb; 172(4):1124-35. PubMed ID: 25339241
    [Abstract] [Full Text] [Related]

  • 29. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL, Schaus JM, Gehlert DR.
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The peripheral dopaminergic system: morphological analysis, functional and clinical applications.
    Amenta F, Ricci A, Tayebati SK, Zaccheo D.
    Ital J Anat Embryol; 2002 Sep; 107(3):145-67. PubMed ID: 12437142
    [Abstract] [Full Text] [Related]

  • 33. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus.
    Flores G, Barbeau D, Quirion R, Srivastava LK.
    J Neurosci; 1996 Mar 15; 16(6):2020-6. PubMed ID: 8604046
    [Abstract] [Full Text] [Related]

  • 34. Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.
    Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD.
    Psychopharmacology (Berl); 1995 Feb 15; 117(4):403-12. PubMed ID: 7604140
    [Abstract] [Full Text] [Related]

  • 35. D2 and D1 dopaminergic activity of 7-OH-DPAT.
    Sethy VH, Ellerbrock BR, Fici GJ, Wu H.
    Brain Res; 1996 Sep 09; 733(1):41-5. PubMed ID: 8891246
    [Abstract] [Full Text] [Related]

  • 36. Light microscope autoradiography of peripheral dopamine receptor subtypes.
    Amenta F.
    Clin Exp Hypertens; 1997 Sep 09; 19(1-2):27-41. PubMed ID: 9028633
    [Abstract] [Full Text] [Related]

  • 37. Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen.
    Mignini F, Tomassoni D, Traini E, Amenta F.
    J Neuroimmunol; 2009 Jan 03; 206(1-2):5-13. PubMed ID: 19012970
    [Abstract] [Full Text] [Related]

  • 38. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S.
    J Pharmacol Exp Ther; 1995 Nov 03; 275(2):885-98. PubMed ID: 7473180
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Behavioural effects of 7-OH-DPAT are solely due to stimulation of dopamine D2 receptors in the shell of the nucleus accumbens; jaw movements.
    Koshikawa N, Miwa Y, Adachi K, Kobayashi M, Cools AR.
    Eur J Pharmacol; 1996 Jul 25; 308(3):227-34. PubMed ID: 8858292
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.